Rare Disease Company Seeks 100 Drugs in 10 Years

Recursion Pharmaceuticals has set the audacious goal for itself of developing 100 drugs in 10 years for rare diseases. The company, focused on repurposing compounds abandoned in clinical development by other drugmakers, thinks it can achieve this by a fundamentally different approach to drug development than the industry’s traditional process of screening compounds against potential disease targets. We spoke to Chris Gibson, founder and CEO of Recursion, about the approach his company is taking, whether rare diseases particularly lend themselves to it, and whether it has implications more broadly for drug development.